Thromb Haemost 2012; 108(06): 1246-1248
DOI: 10.1160/TH12-08-0556
Letters to the Editor
Schattauer GmbH

Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term

Chiara Giannarelli*
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Giovanni Cimmino*
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Borja Ibanez
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
2   CNIC, Madrid, Spain
,
Giulia Chiesa
3   Dipartimento di Scienze Farmacologiche e Biomoleculari, Universitàdegli Studi di Milano, Milan, Italy
,
Jaime Garcia-Prieto
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Carlos G. Santos-Gallego
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Matilde Alique-Aguilar
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
,
Valentin Fuster
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
2   CNIC, Madrid, Spain
,
Cesare Sirtori
3   Dipartimento di Scienze Farmacologiche e Biomoleculari, Universitàdegli Studi di Milano, Milan, Italy
,
Juan J. Badimon
1   AtheroThrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine;New York, New York, USA
› Author Affiliations

Financial support:This study was supported in part by Pfizer, manufacturer of recombinant apoA-I Milano (ETC-216).
Further Information

Publication History

Received: 06 August 2012

Accepted after major revision:12 September 2012

Publication Date:
30 November 2017 (online)

Preview

 

* Authors contributed equally to this work.